The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response

Journal of Urology

Volumn 160, Issue 4, 1998, Pages 1358-1367

  Lepor, Herbert ^a   Williford, William O ^a   Barry, Michael J ^a   Haakenson, Clair ^a   Jones, Karen ^a  

^a NONE

Author keywords

Drug therapy; Finasteride; Placebos; Prostatic hypertrophy

Indexed keywords

FINASTERIDE; TERAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; URINE FLOW RATE;

EID: 0032322493     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62536-9     Document Type: Article

References (36)

1. Lepor, H.: Alpha blockade for the treatment of benign prostatic hyperplasia. Urol. Clin. N. Amer., 22: 375, 1995.
2. Lepor, H.: Medical therapy for benign prostatic hyperplasia. Urology, 42: 483, 1993.
3. McConnell, J. D.: Benign prostatic hyperplasia hormonal treatment. Urol. Clin. N. Amer., 22: 387, 1995.
4. Lepor, H.: Natural history, evaluation and nonsurgical management of benign prostatic hyperplasia. Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W.B. Saunders, vol. 2, chapt. 47, pp. 1453-1478, 1998.
5. Shapiro, E. and Lepor, H.: Pathophysiology of clinical benign prostatic hyperplasia. Urol. Clin. N. Amer., 22: 285, 1995.
6. Lepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G. and Madsen, P.: A randomized multicenter placebo controlled study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol., 148: 1467, 1992.
7. Brawer, M. K., Adams, G., Epstein, H. and the Terazosin Benign Prostatic Hyperplasia Study Group: Terazosin in the treatment of benign prostatic hyperplasia. Arch. Fam. Med., 2: 929, 1993.
8. Elihali, M., Ramsey, E. W., Barkin, J., Casey, R. W., Boake, R. C., Beland, G., Fradet, Y., Inachtenberg, J., Onovan, W. L., Schick, E. and Klotz, L. H.: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology, 47: 335, 1996.
9. Roehrborn, C. G., Oesterling, J. E., Lloyd, K., Lynch, J. and Padley, R. J. for the HYCAT Investigator Group: Hytrin community assessment trial (HYCAT): evaluation of the clinical effectiveness of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyperplasia. J. Urol., part 2, 153: 272A, abstract 175, 1995.
10. Chapple, C. R., Carter, P., Christmas, T. J., Kirby, R. S., Bryan, J., Milroy, E. J. and Abrams, P.: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74: 50, 1994.
11. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Ray, J., Goffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled dose response multicenter study. J. Urol., 154: 110, 1995.
12. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
13. Kawabe, K., Ueno, A., Takimota, Y., Aso, Y., Kato, H. and YM617 Clinical Study Group: Use of an al-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol., 144: 908, 1990.
14. 1c adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction. Brit. J. Urol., 76: 325, 1995.
15. 1c antagonist. J. Urol., part 2, 153: 274A, abstract 182, 1995.
16. Stone, N., Lepor, H., Crawford, E. D., Narayan, P., Das, S., Schellhammer, P. E. and Klimberg, I. W.: Dose ranging study of the antiandrogen flutamide in men with benign prostatic hyperplasia (BPH): effect on prostate volume and serum prostate specific antigen (PSA) level. J. Urol., part 2, 155: 575A. abstract 1059, 1996.
17. Berger, B. M., Naadimuthu, A., Boddy, A., Fisher, H. A., McConnell, J. D., Milam, D., Mobley, D. and Rajfer, J. for the Zanoterone Study Group: The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. J. Urol., 154: 1060, 1995.
18. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S. and the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. New Engl. J. Med., 327: 1185, 1992.
19. Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate, 22: 291, 1993.
20. Andersen, J. T., Ekman, P., Wolf, H., Beisland, H. O., Johanssen, J. E., Kontturi, M., Lehtonen, T., Tveter, K. and the Scandinavian BPH Study Group: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology, 46: 631, 1995.
21. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P. and Padley, R. J.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med., 335: 533, 1996.
22. Barry, M. J., Fowler, F. J., Jr., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K. and the Measurement Committee of the American Urological Association: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med. Care, 33: AS145, 1995.
23. Barry M. J., Fowler, F. J., Jr., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K. and the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol., 148: 1549, 1992.
24. Barry, M. J. and O'Leary, M. P.: Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol. Clin. N. Amer., 22: 299, 1995.
25. Greene, D. R., Egawa, S., Hellerstein, D. K. and Scardino, P. T.: Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology, 36: 293, 1990.
26. Schluchter, M.: BMDP-5V unbalanced repeated measures models with structured covariance matrices. Technical Report Number 86. Los Angeles: BMDP Statistical Software, 1988.
27. Miller, R. J.: Simultaneous Statistical Inference. New York: McGraw-Hill, 1960.
28. Boyle, P., Gould, A. and Roehrborn, C. J.: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 48: 398, 1966.
29. Girman, C. J., Jacobsen, S. J., Guess, H. A., Oesterling, J. E., Chute, C. J., Panser, L. A. and Lieber, M. M.: Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J. Urol., 153: 1510, 1995.
30. Van Venrooij, G. E. P. M., Boon, T. A. and de Gier, R. P. E.: International Prostate Symptom Score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J. Urol., 153: 1516, 1995.
31. Barry, M. J., Cockett, A. T. K., Holtgrewe, H. L., McConnell, J. D., Sihelnik, S. A. and Winfield, H. N.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol., 150: 351, 1993.
32. Kaplan, S. A., Te, A. E., Pressler, L. B. and Olsson, C. A.: Transition zone index as a method of assessing benign prostatic hyperplasia: Correlation with symptoms, urine flow and detrusor pressure. J. Urol., 154: 1764, 1995.
33. Berry, S. J., Coffey, D. S., Walsh, P. C. and Ewing, L. L.: The development of human prostatic hyperplasia with age. J. Urol., 132: 474, 1984.
34. Barry, M. J., Williford, W. O., Chang, Y., Machi, M., Jones, K. M., Walker-Corkery, E. and Lepor, H.: Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J. Urol., 154: 1770, 1995.
35. Lepor, H., Nieder, A., Fesser, J., O'Connell, C. and Dixon, C.: Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology, 49: 476, 1997.
36. McConnell, J. D., Bruskewitz, R., Walsh, P. C., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M. and Waldstreicher, J.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl. J. Med., 328: 557, 1998.